Bone marrow/allograft component therapy. A clinical trial.
Bone graft is required in clinical orthopedic situations that involve a skeletal defect. Whether the defect is the result of trauma or surgery, autogenous iliac bone graft is the gold standard of therapy. The author used autogenous bone marrow/cancellous allograft as a bone graft substitute in 19 consecutive patients with a bony defect (synthetic bone substitutes were not available commercially when the series began). In this prospective study, both clinical and radiographic outcomes were followed. Of the patients, 100% were clinically healed at the site of grafting; 95% achieved radiographic union. No patients had surgical or postoperative complications. A bone marrow/allograft is a viable alternative to an iliac bone graft.
Skoff
H D
HD
Harvard Medical School, Beth Israel Hospital, Boston, Massachusetts, USA.
D000328:Adult; D000368:Aged; D001847:Bone Diseases / Q000601:surgery*; D016026:Bone Marrow Transplantation / Q000379:methods*; D016025:Bone Transplantation / Q000379:methods*; D015331:Cohort Studies; D005260:Female; D005271:Femur Head Necrosis / Q000601:surgery; D050723:Fractures, Bone / Q000601:surgery*; D018460:Fractures, Comminuted / Q000601:surgery; D017759:Fractures, Malunited / Q000601:surgery; D005599:Fractures, Ununited / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000601:surgery; D011446:Prospective Studies; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous